Prostate cancer, version 3.2024 Guidelines
| Authors: | Schaeffer, E. M.; Srinivas, S.; Adra, N.; An, Y.; Bitting, R.; Chapin, B.; Cheng, H. H.; D'Amico, A. V.; Desai, N.; Dorff, T.; Eastham, J. A.; Farrington, T. A.; Gao, X.; Gupta, S.; Guzzo, T.; Ippolito, J. E.; Karnes, R. J.; Kuettel, M. R.; Lang, J. M.; Lotan, T.; McKay, R. R.; Morgan, T.; Pow-Sang, J. M.; Reiter, R.; Roach, M.; Robin, T.; Rosenfeld, S.; Shabsigh, A.; Spratt, D.; Szmulewitz, R.; Teply, B. A.; Tward, J.; Valicenti, R.; Wong, J. K.; Snedeker, J.; Freedman-Cass, D. A. |
| Title: | Prostate cancer, version 3.2024 |
| Abstract: | The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel's discussions for the 2024 update to the guidelines with regard to initial risk stratification, initial management of very-low-risk disease, and the treatment of nonmetastatic recurrence. |
| Keywords: | risk assessment; prostatic neoplasms; prostate tumor; neoplasms, second primary; humans; human; male; second primary neoplasm |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 22 |
| Issue: | 3 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2024-04-01 |
| Start Page: | 140 |
| End Page: | 150 |
| Language: | English |
| DOI: | 10.6004/jnccn.2024.0019 |
| PUBMED: | 38626801 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Source: Scopus |
